Company: CERO
Filing Date: 2025-05-15
Form Type: 10-Q
Source: 0001213900-25-044335
Chunk: 274

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-05-15
Form: 10-Q
Item: Part II, Item 2
Chunk 274
---
Item 2. Unregistered Sales of Equity Securities
and Use of Proceeds

On January 6, 2025, 625 Series A Preferred Warrants were exercised
into 625 shares of Series A Preferred Stock for gross cash proceeds of $500,000.

On January 6, 2025, the Company issued warrants
to purchase an aggregate of 163,853 shares of Common Stock to a certain investor affiliated with each other to induce investors to exercise
their Series A Preferred Warrants for cash (the “January 2025 Common Warrants”). The January 2025 Common Warrants are initially
exercisable for cash at an initial exercise price equal to $5.82 (as adjusted for stock splits, stock dividends, stock combinations, recapitalizations
and similar events). The January 2025 Common Warrants are exercisable beginning six months after the issuance date (the “Initial
Exercisability Date”) and expire on the third anniversary of the Initial Exercisability Date. The January 2025 Common Warrants require
“buy-in” payments to be made by us for failure to deliver any shares of Common Stock issuable upon exercise. If at the time
of exercise of the January 2025 Common Warrants, there is no effective registration statement registering the shares of the Common Stock
underlying the January 2025 Common Warrants, such warrants may be exercised on a cashless basis pursuant to their terms.

On March 10, 2025, the Company redeemed 316 shares of Series C Preferred
Stock from certain investors for a cash payment of $395,000, or $1,250 per share of Series C Preferred Stock.

Item 3. Defaults Upon Senior Securities

None.

Item 4. Mine Safety Disclosures

Not applicable.

Item 5. Other Information

From time to time, our officers (as defined in
Rule 16a–1(f)) and directors may enter into Rule 10b5-1 or non-Rule 10b5-1 trading arrangements (as each such term is defined in
Item 408 of Regulation S-K). None of our directors or “officers,” as defined in Rule 16a-1(f) under the Securities Exchange
Act of 1934, adopted or terminated a Rule 10b5-1 trading plan or arrangement or a non-Rule 10b5-1 trading plan or arrangement, as defined
in Item 408(c) of Regulation S-K,